Warning letter
Abbott's Compounding Pharmacy, Inc.: warning letter of Apr 4, 2017
FDA warning letter 506776 · San Francisco District Office
Key facts
| Reference number | 506776 |
|---|---|
| Company | Abbott's Compounding Pharmacy, Inc. |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Apr 4, 2017 |
| Posted date | Apr 4, 2017 |
| Issuing office | San Francisco District Office |
| Product type | Drugs |
| CFR sections cited | 211.42(c)(10)(iv), 211.42(c)(10)(v), 211.113(b), 211.56(a), 201.115, 211, 211.28(a), 211.42(b), 211.42(c)(10)(iii) |
| Inspection city | Berkeley |
| Inspection ZIP | 94705 |
| Inspection start date | Dec 29, 2015 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: